Skip to main content

Advertisement

SpringerLink
Log in

Hepatitis B and C Virus Reactivation Patterns in a Romanian Cohort of Patients with Chronic Lymphoproliferative Disorders

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Hepatitis B and C virus (HBV and HCV) reactivations have become more common following the intensive use of biological therapies for the treatment of chronic lymphoproliferative disorders (CLD). We evaluate risk factors for virus reactivation and exitus in patients diagnosed with CLD and HBV or HCV infection, undergoing rituximab-chemotherapy (R-chemo). A prospective, observational study in two tertiary-care Romanian hospitals, between December 2007 and May 2010, of patients diagnosed with CLD undergoing R-chemo. HBV and HCV serological markers, viral load, fibrosis and necroinflammation were assessed at baseline and every 3–6 months. We screened 502 patients diagnosed with CLDs (77.2% non-Hodgkin lymphomas) and enrolled 57 patients with HBV and/or HCV infection with a mean age of 61.35 ± 11.1 years. The replicative virus was HBV in 23 patients (40.3%), HCV in 33 patients (57.9%). HCV reactivation rate (15.6%) was lower than for HBV (45.5%) (p = 0.02). In univariate analysis, viral reactivation was associated with aggressive CLD (p = 0.01), HBV (p = 0.01) and lymphopenia (p = 0.02). Death was associated with aggressive CLD (p = 0.01), viral reactivation (p = 0.001) and high baseline viremia (p = 0.05). In multivariate analysis, viral reactivation was associated with lymphopenia (OR 0.05, 95% CI 0.003–0.85, p = 0.03). Risk of death was 10 times higher for patients with viral reactivation (95% CI 1.54–65.5, p = 0.01). A quarter of the infected patients were diagnosed with viral reactivation. While hepatitis C was more prevalent than hepatitis B in patients with CLD, viral reactivation was found 3 times more frequently in patients with hepatitis B than C.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Abbreviations

HBV:

Hepatitis B virus

HCV:

Hepatitis C virus

CLD:

Chronic lymphoproliferative disorder

NHL:

Non-Hodgkin lymphoma

CHB:

Chronic hepatitis B

CHC:

Chronic hepatitis C

R-chemo:

Rituximab-chemotherapy

References

  1. Popovici O, Molnar G, Janta D (2014) Rezultatele studiului sero-epidemiologic de prevalenta pentru infectia cu virus hepatitic B si virus hepatitic C. In: National conference of microbiology and epidemiology (Conferinta Nationala de Microbiologie si Epidemiologie), Bucharest, 13–15 November 2014

  2. Dal Maso L, Franceschi S (2006) Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomark Prev 15:2078–2085

    Article  Google Scholar 

  3. Nath A, Agarwal R, Malhotra P, Varma S (2010) Prevalence of hepatitis B virus infection in non-Hodgkin’s lymphoma: a systematic review and meta-analysis. Intern Med J 40:633–641

    Article  CAS  PubMed  Google Scholar 

  4. Marcucci F, Mele A (2011) Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis and therapeutic opportunities. Blood 117(6):1792–1798

    Article  CAS  PubMed  Google Scholar 

  5. American Association for the Study of liver diseases emerging trends conference, Reactivation of Hepatitis B, Arlington: March 21–22, 2013

  6. Harris NE, Jaffe ES, Stein H (1994) A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392

    CAS  PubMed  Google Scholar 

  7. Harris NL (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. Ann Oncol 10:1419–1432

    Article  CAS  PubMed  Google Scholar 

  8. Swerldlow SH, Campo E, Harris NL (2008) In: WHO classification of tumours of haematopietic and lymphoid tissues. International Agency for Research in Cancer/IACRS Press, Lyon

  9. Porter RS, Kaplan JL (2011) Neutropenia and lymphocytopenia, chap 107. In: Merck manual of diagnosis and therapy, 19th edn. Merck Sharp Dohme Corp., Whitehouse Station

  10. Kawsar Hameem I, Shahnewaz J, Gopalakrishna KV, Spiro TP, Daw HA (2012) Role of prechemotherapy screening and antiviral prophylaxis. Clin Adv Hematol Oncol 10(6):370–378

    PubMed  Google Scholar 

  11. Nosotti L, D’Andrea M, Pitidis A (2012) Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin’s lymphoma patients treated with immunochemotherapy. Scand J Infect Dis 44:70–73

    Article  CAS  PubMed  Google Scholar 

  12. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62(3):299–307

    Article  CAS  PubMed  Google Scholar 

  13. Yang F, Zhu HL, He C, Li JJ, Xiang B, Cui X et al (2014) Effect of antiviral prophylaxis strategy for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma patients with hepatitis B virus infection: a retrospective cohort study. Indian J Hematol Blood Transfus 30(2):97–104

    Article  PubMed  Google Scholar 

  14. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148(7):519–528

    Article  PubMed  PubMed Central  Google Scholar 

  15. Yeo W, Johnson P (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43(2):209–220

    Article  CAS  PubMed  Google Scholar 

  16. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182–188

    Article  CAS  PubMed  Google Scholar 

  17. Drugan C, Brichler S, Muntean M, Olteanu I, Carstina D, Drugan T et al (2008) Genotipe of hepatitis B virus in Romanian patients. Appl Med Inform 22(1–2):27–32

    Google Scholar 

  18. Constantinescu I, Dinu AA, Boscaiu V, Niculescu M (2014) Hepatitis B virus core promoter mutations in patients with chronic hepatitis B and hepatocellular carcinoma in Bucharest, Romania. Hepat Mon 14(10):e22072

    Article  PubMed  PubMed Central  Google Scholar 

  19. Carman WF, Fagan EA, Hadziyannis S, Karayiannis P, Tassopoulos NC, Williams R (1991) Association of a precore genomic variant of HBV with fulminant hepatitis. Hepatology 14(2):219–222

    Article  CAS  PubMed  Google Scholar 

  20. Yeo W, Zhong S, Chan PKS, Ho WM, Wong HTM, Chan ASK (2000) Sequence variations of precore/core and precore promoter regions of hepatitis B virus in patients with or without viral reactivation during cytotoxic chemotherapy. J Viral Hepat 7:448–458

    Article  CAS  PubMed  Google Scholar 

  21. Nagamatsu H, Kumashiro R, Itano S, Matsugaki S, Sata M (2003) Investigation of associating factors in exacerbation of liver damage after chemotherapy in patients with HBV-related HCC. Hepatol Res 26:293–301

    Article  PubMed  Google Scholar 

  22. Cheng AL, Hsiung CA, Su IJ, Chang MC, Tsao CJ, Kao WY et al (2003) Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37:1320–1328

    Article  CAS  PubMed  Google Scholar 

  23. Markovic S, Drozina G, Vovk M, Fidler-Jenko M (1999) Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 46(29):2925–2930

    CAS  PubMed  Google Scholar 

  24. Liang R, Lau GK, Kwong YL (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17:394–398

    Article  CAS  PubMed  Google Scholar 

  25. Lee GW, Ryu MH, Lee JL, Oh S, Kime E, Lee JH et al (2003) The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin’s lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 18:849–854

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY et al (2006) Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59–68

    Article  CAS  PubMed  Google Scholar 

  27. Vento S, Cainelli F, Mirandola F, Cosco L, Di Perri G, Solbiati M et al (1996) Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 347:92–93

    Article  CAS  PubMed  Google Scholar 

  28. Lim R, Holt A (2014) Hepatitis B and C prophylaxis in patients receiving chemotherapy. Viral Hepat Pract 6(1):10–13

    PubMed  PubMed Central  Google Scholar 

  29. Faggioli P, De Paschale M, Tocci A, Luoni M, Fava S, De Paoli A et al (1997) Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin’s lymphoma. Haematologica 82:38–42

    CAS  PubMed  Google Scholar 

  30. Torres HA, Davila M (2012) Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 9:156–166

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The current study belongs to a national Grant PNCDI-II/41-012/2007, known as LIMFO-VIR.

Author information

Authors and Affiliations

  1. National Institute for Infectious Diseases “Prof. Dr. Matei Balş”, 1st Grozovici Street, 021105, Bucharest, Romania

    Violeta Molagic, Raluca Mihailescu, Catalin Tiliscan, Cristina Popescu, Remulus Catana, Mihaela Radulescu & Victoria Arama

  2. Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Street, 050474, Bucharest, Romania

    Catalin Tiliscan, Cristina Popescu, Ana Maria Vladareanu, Mihaela Radulescu, Victoria Arama & Stefan Sorin Arama

  3. Department of Hematology, University Emergency Hospital Bucharest, 169 Splaiul Independentei Street, 050098, Bucharest, Romania

    Ana Maria Vladareanu

Authors
  1. Violeta Molagic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raluca Mihailescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catalin Tiliscan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cristina Popescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ana Maria Vladareanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Remulus Catana
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mihaela Radulescu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Victoria Arama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Stefan Sorin Arama
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors had equal contributions in writing this paper.

Corresponding author

Correspondence to Violeta Molagic.

Ethics declarations

Conflict of interest

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Ethical Standard

This study was approved by the Ethics Committee of the National Institute for Infectious Diseases “Prof. Dr. Matei Balş” and the University Emergency Hospital Bucharest, Bucharest, Romania.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Molagic, V., Mihailescu, R., Tiliscan, C. et al. Hepatitis B and C Virus Reactivation Patterns in a Romanian Cohort of Patients with Chronic Lymphoproliferative Disorders. Indian J Hematol Blood Transfus 35, 459–464 (2019). https://doi.org/10.1007/s12288-018-01063-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-018-01063-9

Keywords

Search

Navigation